Skip to main content
Top
Published in: Trials 1/2013

Open Access 01-12-2013 | Methodology

Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program

Authors: Spencer Phillips Hey, Charles M Heilig, Charles Weijer

Published in: Trials | Issue 1/2013

Login to get access

Abstract

Background

Maximizing efficiency in drug development is important for drug developers, policymakers, and human subjects. Limited funds and the ethical imperative of risk minimization demand that researchers maximize the knowledge gained per patient-subject enrolled. Yet, despite a common perception that the current system of drug development is beset by inefficiencies, there remain few approaches for systematically representing, analyzing, and communicating the efficiency and coordination of the research enterprise. In this paper, we present the first steps toward developing such an approach: a graph-theoretic tool for representing the Accumulating Evidence and Research Organization (AERO) across a translational trajectory.

Methods

This initial version of the AERO model focuses on elucidating two dimensions of robustness: (1) the consistency of results among studies with an identical or similar outcome metric; and (2) the concordance of results among studies with qualitatively different outcome metrics. The visual structure of the model is a directed acyclic graph, designed to capture these two dimensions of robustness and their relationship to three basic questions that underlie the planning of a translational research program: What is the accumulating state of total evidence? What has been the translational trajectory? What studies should be done next?

Results

We demonstrate the utility of the AERO model with an application to a case study involving the antibacterial agent, moxifloxacin, for the treatment of drug-susceptible tuberculosis. We then consider some possible elaborations for the AERO model and propose a number of ways in which the tool could be used to enhance the planning, reporting, and analysis of clinical trials.

Conclusion

The AERO model provides an immediate visual representation of the number of studies done at any stage of research, depicting both the robustness of evidence and the relationship of each study to the larger translational trajectory. In so doing, it makes some of the invisible or inchoate properties of the research system explicit – helping to elucidate judgments about the accumulating state of evidence and supporting decision-making for future research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tall AR, Yvan-Charvet L, Wang N: The Failure of Torcetrapib: Was it the molecule or the mechanism?. Arteriosclerosis, Thrombosis, Vasc Biol. 2007, 27: 257-260.CrossRef Tall AR, Yvan-Charvet L, Wang N: The Failure of Torcetrapib: Was it the molecule or the mechanism?. Arteriosclerosis, Thrombosis, Vasc Biol. 2007, 27: 257-260.CrossRef
2.
go back to reference Joy TR, Hegele RA: The failure of torcetrapib: what have we learned?. British J Pharmacol. 2008, 154: 1379-1381.CrossRef Joy TR, Hegele RA: The failure of torcetrapib: what have we learned?. British J Pharmacol. 2008, 154: 1379-1381.CrossRef
3.
go back to reference Zhao L, Jin W, Rader D, Packard C, Feuerstein G: A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Biochem Pharmacol. 2009, 78: 315-325.CrossRefPubMed Zhao L, Jin W, Rader D, Packard C, Feuerstein G: A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Biochem Pharmacol. 2009, 78: 315-325.CrossRefPubMed
4.
go back to reference Arrowsmith J: Phase II failures: 2008-2010. Nat Rev Drug Discov. 2011, 10: 1-CrossRef Arrowsmith J: Phase II failures: 2008-2010. Nat Rev Drug Discov. 2011, 10: 1-CrossRef
5.
go back to reference Morgan P, Graaf PHVD, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA: Can the flow of medicines be improved? Fundamental pharamacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012, 17: 419-424.CrossRefPubMed Morgan P, Graaf PHVD, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA: Can the flow of medicines be improved? Fundamental pharamacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012, 17: 419-424.CrossRefPubMed
6.
go back to reference Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004, 3: 711-715.CrossRefPubMed Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004, 3: 711-715.CrossRefPubMed
7.
go back to reference Arrowsmith J: Phase III and submission failures: 2007–2010. Nat Rev Drug Discov. 2011, 10: 1-CrossRef Arrowsmith J: Phase III and submission failures: 2007–2010. Nat Rev Drug Discov. 2011, 10: 1-CrossRef
8.
go back to reference Boucher HW, Talbot GH, Bradley JSJr, JEE Gilbert, Bartlett J, Rice LB: Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48: 1-12.CrossRefPubMed Boucher HW, Talbot GH, Bradley JSJr, JEE Gilbert, Bartlett J, Rice LB: Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48: 1-12.CrossRefPubMed
9.
go back to reference Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Blanc ML, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D: The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010, 16: 1764-1769.CrossRefPubMedPubMedCentral Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Blanc ML, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D: The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010, 16: 1764-1769.CrossRefPubMedPubMedCentral
11.
go back to reference Hey SP: Meta-heuristic strategies in scientific judgment. 2011, University of Western Ontario Hey SP: Meta-heuristic strategies in scientific judgment. 2011, University of Western Ontario
13.
go back to reference Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov. 2011, 10: 712-713.CrossRefPubMed Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov. 2011, 10: 712-713.CrossRefPubMed
14.
15.
go back to reference Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J: In Vitro and In Vivo activities of Moxifloxacin and Clinafloxacin against mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998, 42: 2066-2069.PubMedPubMedCentral Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J: In Vitro and In Vivo activities of Moxifloxacin and Clinafloxacin against mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998, 42: 2066-2069.PubMedPubMedCentral
16.
go back to reference Gillespie S, Billington O: Activity of Moxifloxacin against Mycobacteria. J Antimicrob Chemother. 1999, 44: 393-395.CrossRefPubMed Gillespie S, Billington O: Activity of Moxifloxacin against Mycobacteria. J Antimicrob Chemother. 1999, 44: 393-395.CrossRefPubMed
17.
go back to reference Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V: Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: evaluation of In Vitro and Pharmacodynamic indices that best predict In Vivo efficacy. Antimicrob Agents Chemother. 2007, 51: 576-582.CrossRefPubMed Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V: Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: evaluation of In Vitro and Pharmacodynamic indices that best predict In Vivo efficacy. Antimicrob Agents Chemother. 2007, 51: 576-582.CrossRefPubMed
18.
go back to reference Miyazaki E, Miyazaki M, Chen J, Chaisson R, Bishai W: Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother. 1999, 43: 85-89.CrossRefPubMedPubMedCentral Miyazaki E, Miyazaki M, Chen J, Chaisson R, Bishai W: Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother. 1999, 43: 85-89.CrossRefPubMedPubMedCentral
19.
go back to reference Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O’Brien R, Vernon A, Roscigno G, Grosset J: Effectiveness of once-weekly Rifapentine and Moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 2001, 45: 3482-3486.CrossRefPubMedPubMedCentral Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O’Brien R, Vernon A, Roscigno G, Grosset J: Effectiveness of once-weekly Rifapentine and Moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 2001, 45: 3482-3486.CrossRefPubMedPubMedCentral
20.
go back to reference Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J: Bactericidal activity of increasing daily and weekly doses of Moxifloxacin in Murine tuberculosis. Antimicrob Agents Chemother. 2002, 46: 1875-1879.CrossRefPubMedPubMedCentral Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J: Bactericidal activity of increasing daily and weekly doses of Moxifloxacin in Murine tuberculosis. Antimicrob Agents Chemother. 2002, 46: 1875-1879.CrossRefPubMedPubMedCentral
21.
go back to reference Nuermberger E, Yoshimatsu T, Tyagi S, O’Brien R, Vernon A, Chaisson R, Bishai W, Grosset J: Moxifloxacin-containing regimen greatly reduces time to culture conversion in Murine tuberculosis. Am J Respir Crit Care Med. 2004, 169: 421-426.CrossRefPubMed Nuermberger E, Yoshimatsu T, Tyagi S, O’Brien R, Vernon A, Chaisson R, Bishai W, Grosset J: Moxifloxacin-containing regimen greatly reduces time to culture conversion in Murine tuberculosis. Am J Respir Crit Care Med. 2004, 169: 421-426.CrossRefPubMed
22.
go back to reference Gosling R, Uiso L, Sam N, Bongard E, Kanduma E, Nyindo M, Morris R, Gillespie S: The bactericidal activity of Moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003, 168: 1342-1345.CrossRefPubMed Gosling R, Uiso L, Sam N, Bongard E, Kanduma E, Nyindo M, Morris R, Gillespie S: The bactericidal activity of Moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003, 168: 1342-1345.CrossRefPubMed
23.
go back to reference Pletz M, Roux AD, Roth A, Neumann K, Mauch H, Lode H: Early bactericidal activity of Moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother. 2004, 48: 780-782.CrossRefPubMedPubMedCentral Pletz M, Roux AD, Roth A, Neumann K, Mauch H, Lode H: Early bactericidal activity of Moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother. 2004, 48: 780-782.CrossRefPubMedPubMedCentral
24.
go back to reference Gillespie S, Gosling R, Uiso L, Sam N, Kanduma E, McHugh T: Early bactericidal activity of a Moxifloxacin and Isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother. 2005, 56: 1169-1171.CrossRefPubMed Gillespie S, Gosling R, Uiso L, Sam N, Kanduma E, McHugh T: Early bactericidal activity of a Moxifloxacin and Isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother. 2005, 56: 1169-1171.CrossRefPubMed
25.
go back to reference Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K, Jankus D, Debanne S, Charlebois E: Maciel E, et al.: Early and extended early bactericidal activity of Levofloxacin, Gatifloxacin and Moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006, 10: 605-612.PubMed Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K, Jankus D, Debanne S, Charlebois E: Maciel E, et al.: Early and extended early bactericidal activity of Levofloxacin, Gatifloxacin and Moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006, 10: 605-612.PubMed
26.
go back to reference Nijland HMJ, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel, Aarnoutse RE: Rifampicin reduces plasma concentrations of Moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007, 45: 1001-1007.CrossRefPubMed Nijland HMJ, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel, Aarnoutse RE: Rifampicin reduces plasma concentrations of Moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007, 45: 1001-1007.CrossRefPubMed
27.
go back to reference Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, Johnson JL: Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008, 52: 852-857.CrossRefPubMed Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, Johnson JL: Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008, 52: 852-857.CrossRefPubMed
28.
go back to reference Burman W, Goldberg S, Muzanye JJG, Engle M, Mosher A, Choudhri S, Daley C, Munsiff S: Zhao Z, et al.: Moxifloxacin versus Ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006, 174: 331-338.CrossRefPubMed Burman W, Goldberg S, Muzanye JJG, Engle M, Mosher A, Choudhri S, Daley C, Munsiff S: Zhao Z, et al.: Moxifloxacin versus Ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006, 174: 331-338.CrossRefPubMed
29.
go back to reference Rustomjee R, Lienhardt C, Kanyok T, for TB (OFLOTUB) study team G: A phase II study of the sterilising activities of Ofloxacin, Gatifloxacin and Moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008, 12: 128-138.PubMed Rustomjee R, Lienhardt C, Kanyok T, for TB (OFLOTUB) study team G: A phase II study of the sterilising activities of Ofloxacin, Gatifloxacin and Moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008, 12: 128-138.PubMed
30.
go back to reference Conde M, Efron A, Loredo C, Souza GD, Gracxa N, Cezar M, Ram M, Chaudhary M, Bishai W, Kritski A, Chaisson R: Moxifloxacin versus Ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009, 53: 1314-1319. Conde M, Efron A, Loredo C, Souza GD, Gracxa N, Cezar M, Ram M, Chaudhary M, Bishai W, Kritski A, Chaisson R: Moxifloxacin versus Ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009, 53: 1314-1319.
31.
go back to reference Dorman S, Johnson J: Goldberg S, et al.: Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009, 180: 273-280.CrossRefPubMed Dorman S, Johnson J: Goldberg S, et al.: Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009, 180: 273-280.CrossRefPubMed
32.
go back to reference Wang JY, Wang JT, Tsai T, Hsu C, Yu C, Hsueh P, Lee L, Yang P: Adding Moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009, 14: 65-71. Wang JY, Wang JT, Tsai T, Hsu C, Yu C, Hsueh P, Lee L, Yang P: Adding Moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009, 14: 65-71.
33.
go back to reference Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K: A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009, 62: 464-475.CrossRefPubMed Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K: A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009, 62: 464-475.CrossRefPubMed
34.
go back to reference Langan D, Higgins JPT, Gregory W, Sutton AJ: Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol. 2012, 65: 511-519.CrossRefPubMed Langan D, Higgins JPT, Gregory W, Sutton AJ: Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol. 2012, 65: 511-519.CrossRefPubMed
Metadata
Title
Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program
Authors
Spencer Phillips Hey
Charles M Heilig
Charles Weijer
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Trials / Issue 1/2013
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-14-159

Other articles of this Issue 1/2013

Trials 1/2013 Go to the issue